Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-07-12
2011-07-12
Dahle, Chun (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S138100, C424S141100, C424S143100, C424S144100, C424S152100, C424S153100, C424S155100, C424S156100
Reexamination Certificate
active
07976838
ABSTRACT:
The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor.
REFERENCES:
patent: 4861579 (1989-08-01), Meyer et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5645817 (1997-07-01), Seemann et al.
patent: 5677180 (1997-10-01), Robinson et al.
patent: 5721108 (1998-02-01), Robinson et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 5843439 (1998-12-01), Anderson et al.
patent: 5849898 (1998-12-01), Seed et al.
patent: 6015542 (2000-01-01), Kaminski et al.
patent: 6090365 (2000-07-01), Kaminski et al.
patent: 6120767 (2000-09-01), Robinson et al.
patent: 6171586 (2001-01-01), Lam et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6224866 (2001-05-01), Barbera-Guillem
patent: 6242195 (2001-06-01), Idusogie et al.
patent: 6287537 (2001-09-01), Kaminski et al.
patent: 6368596 (2002-04-01), Ghetie et al.
patent: 6399061 (2002-06-01), Anderson et al.
patent: 6410391 (2002-06-01), Zelsacher
patent: 6455043 (2002-09-01), Grillo-Lopez
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6538124 (2003-03-01), Idusogie et al.
patent: 7708994 (2010-05-01), Benyunes
patent: 7820161 (2010-10-01), Curd et al.
patent: 2002/0004587 (2002-01-01), Miller et al.
patent: 2002/0006404 (2002-01-01), Hanna et al.
patent: 2002/0009444 (2002-01-01), Grillo-Lopez
patent: 2002/0012665 (2002-01-01), Hanna
patent: 2002/0041847 (2002-04-01), Goldenberg
patent: 2002/0128488 (2002-09-01), Yamakawa et al.
patent: 2002/0197255 (2002-12-01), Anderson et al.
patent: 2002/0197256 (2002-12-01), Grewal
patent: 2003/0021781 (2003-01-01), Anderson et al.
patent: 2003/0026801 (2003-02-01), Weiner et al.
patent: 2006/0024300 (2006-02-01), Adams et al.
patent: 2006/0034835 (2006-02-01), Adams et al.
patent: 2009/0155257 (2009-06-01), Adams et al.
patent: 2009/0238762 (2009-09-01), Totoritis et al.
patent: 42 25 853 A 1 (1994-02-01), None
patent: 0 332 865 (1989-09-01), None
patent: 0 330 191 (1996-10-01), None
patent: 1519959 (2005-04-01), None
patent: 1613350 (2009-03-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 95/03770 (1995-02-01), None
patent: WO 98/56418 (1998-12-01), None
patent: WO 98/58964 (1998-12-01), None
patent: WO 99/22764 (1999-05-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 00/09160 (2000-02-01), None
patent: WO 00/20864 (2000-04-01), None
patent: WO 00/27428 (2000-05-01), None
patent: WO 00/27433 (2000-05-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 00/44788 (2000-08-01), None
patent: WO 00/67795 (2000-11-01), None
patent: WO 00/67796 (2000-11-01), None
patent: WO 00/74718 (2000-12-01), None
patent: WO 00/76542 (2000-12-01), None
patent: WO 01/03734 (2001-01-01), None
patent: WO 01/10460 (2001-02-01), None
patent: WO 01/10461 (2001-02-01), None
patent: WO 01/10462 (2001-02-01), None
patent: WO 01/13945 (2001-03-01), None
patent: WO 01/72333 (2001-10-01), None
patent: WO 01/74388 (2001-10-01), None
patent: WO 01/77342 (2001-10-01), None
patent: WO 01/80884 (2001-11-01), None
patent: WO 01/97858 (2001-12-01), None
patent: WO 02/04021 (2002-01-01), None
patent: WO 02/34790 (2002-05-01), None
patent: WO 02/060955 (2002-08-01), None
patent: WO 02/079255 (2002-10-01), None
patent: WO 02/096948 (2002-12-01), None
patent: WO 02/102312 (2002-12-01), None
patent: 03/029296 (2003-04-01), None
patent: WO 03/068821 (2003-08-01), None
patent: WO 2004/003155 (2004-01-01), None
patent: WO 2004/091657 (2004-10-01), None
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines, “Guidelines for the Management of Rheumatoid Arthritis”Arthritis and Rheumatism46(2):328-346 (Feb. 2002).
Anderson et al., “Expression of Human B Cell-Associated Antigens on Leukemias and Lymphomas: A Model of Human B Cell Differentiation”Blood63(6):1424-1433 (1984).
C. Barbas III, et al., “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity”Proc. Natl Acad. Sci. USA91:3809-3813 (Apr 1994).
De Vita et al., “Efficacy of Selective B Cell Blockade in the Treatment of Rheumatoid Arthritis”Arthritis and Rheumatism46(8):2029-2033 (Aug. 2002).
Demidem et al., “Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs”Cancer Biotherapy&Radiopharmaceuticals12(3):177-186 (1997).
Edwards and Cambridge, “Sustained Improvement in Rheumatoid Arthritis Following a Protocol Designed to Deplete B Lymphocytes”Rheumatology40:205-211 (2001).
Edwards et al., “B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders”Biochemical Society Transactions30(part 4):824-828 (2002).
Edwards et al., “Efficacy and safety of Rituximab, a B-cell targeted chimeric monoclonal antibody: A randomized, placebo-controlled trial in patients with rheumatoid arthritis”Arthritis and Rheumatism(Abstract #446) 46(9):S197 (2002).
Einfeld et al., “Molecular Cloning of the Human B Cell CD20 Receptor Predicts a Hydrophobic Protein with Multiple Transmembrane Domains”EMBO Journal7(3):711-717 (1988).
H. Hogrefe, et al., “Creating Randomized Amino Acid Libraries with the QuikChange Multi Site-directed Mutagenesis Kit”BioTechniques33(5):1158-1165 (Nov. 2002).
Higashida et al., “Safety and efficacy of rituximab in the treatment of refractory rheumatoid arthritis”Presented at the annual meeting of the American Society of Hematology(2003).
Higashida et al., “Treatment of DMARD-Refractory Rheumatoid Arthritis With Rituximab”Annual Scientific Meeting of the American College of Rheumatology(Abstract #LB11), New Orleans, LA (Oct. 2002).
Jenkins and Hardy, “Biological modifier therapy for the treatment of rheumatoid arthritis”American Journal of the Medical Sciences323(4):197-205 (2002).
Kiesel et al., “Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis”Leukemia Research11(12):1119-1125 (1987).
Leandro et al., “An open study of B lymphocyte depletion in systemic lupus erythematosus”Article and Rheumatism46(10):2673-2677 (Oct. 2002).
Leandro et al., “B Lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy and dose response”Arthritis and Rheumatism(#1905) 44(9):S370 (2001).
Levine and Pestronk, “IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab”Neurology52(8):1701-1704 (May 12, 1999).
Maloney et al., “The Anti-Tumor Effect of Monoclonal Anti-CD20 Antibody (mAb) Therapy Includes Direct Anti-Proliferative Activity and Induction of Apoptosis in CD20 Positive Non-Hodgkin's Lymphoma (NHL) Cell Lines”Blood(Abstract #2535) 88(10) :637a (1996).
Matthews, R., “Medical Heretics”New Scientist170(2285):34-37 (Apr. 7, 2001).
Nadler et al., “B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes”J. Immunol. 131(1):244-250 (Jul. 1983).
Nadler et al., “Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies”Progress in Hematology, Brown, E., Grune & Stratton, Inc. vol. XII:187-225 (1981).
Nadler, L., “B Cell/Leukemia Panel Workshop: Summary and Comments (Chap. 1)”Leukocyte Typing II, Reinherz et al., Springer Verlag vol. 2:3-37 and Appendix (1986).
Perrotta and Abuel, “Response of Chronic Relapsing ITP of 10 Years Duration to Rituximab”Blood(Abstract #3360) 92(10 Suppl. 1 Part 1-2):88b (1998).
R. Balin
Dahle Chun
Genentech Inc.
Lee Wendy M.
LandOfFree
Therapy of autoimmune disease in a patient with an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapy of autoimmune disease in a patient with an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy of autoimmune disease in a patient with an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2661942